Therefore, the present study aimed to measure the concentrations of ApoE4 and FABP3 in cerebrospinal fluid of patients with AD, MCI and non-demented subjects (CTRL) and compare them to classical biomarkers and a clinical score of cognitive impairment. This evidence concerns the gene FABP3 and Cognitive impairment.